Citations

Clear

16280 citation(s) found for "Yu, David".

Individualized Learning in Robotic Ileal pouch-anal anastomosis
Violante, Tommaso , Sassun, Richard , Mishra, Nitin , Merchea, Amit , Violante, Tommaso , Sassun, Richard , Ferrari, Davide, Behm, Kevin T. , Vierkant, Robert A. , Larson, David W.

Mayo Clinic

Annals of Surgery | August 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006907 | PMID 40792635 Get It

Objective: This study establishes objective benchmarks for robotic ileal pouch-anal anastomosis (IPAA) proficiency, evaluating individual surgeon learning curves using risk-adjusted cumulative sum (RA-CUSUM) analysis. Summary Background Data: IPAA is a standard surgical treatment for conditions like refractory ulcerative colitis; robotic assistance offers potential advantages. However, the robotic IPAA learning curve is not clearly defined. Conventional analyses often overlook significant inter-surgeon variability and patient-specific factors, hindering surgical training optimization. Methods: A multi-site retrospective analysis of 123 consecutive robotic IPAA procedures performed by 11 surgeons between June 2015 and December 2023 was conducted. Patient-related variables were used for risk adjustment, and RA-CUSUM charts were generated to assess 30-day complications, operative time, and length of hospital stay at both aggregate and individual surgeon levels. Results: Aggregate RA-CUSUM data indicated general improvement trends for operative time and length of stay, alongside higher-than-expected complication rates in the early phase. Disaggregated analyses at the individual surgeon level revealed significant heterogeneity in performance trajectories and learning patterns across all three outcomes, directly challenging the concept of a standardized, uniform learning curve. Although postoperative complication and length of stay outcomes did not significantly differ between surgeons, operative time varied significantly. Conclusions: The acquisition of skill in robotic IPAA is a highly individualized process, suggesting the traditional uniform learning curve model is insufficient for contemporary surgical education. These findings strongly advocate for a shift towards personalized training paradigms that incorporate deliberate practice, targeted feedback, and simulation to optimize learning and patient outcomes.
GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
Makwana, Bhargav , Patel, Manav, Panchal, Krisha , Shah, Jui , Kumar, Ashish , Patel, Tirth, Kosiborod, Mikhail, Ramsey, Kathryn Moynihan , Nohria, Anju, Butler, Javed , Ganatra, Sarju , Ramsey, David J. , Dani, Sourbha S. , Khadke, Sumanth , Kosiborod, Mikhail , Fonarow, Gregg C. , Nohria, Anju

Mayo Clinic

JAMA Network Open | August 11, 2025 | Volume: 8 | Issue: 8 | Pages: e2526321

10.1001/jamanetworkopen.2025.26321 | PMID 40788647 Get It

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with increased risk of diabetic retinopathy (DR) and nonarteritic anterior ischemic optic neuropathy (NAION). The risk of sight-threatening complications associated with GLP-1 RAs is underexamined. Objective To investigate whether the use of GLP-1 RAs in patients with T2D is associated with the development of DR, NAION, or DR complications. Design, Setting, and Participants This retrospective cohort study of adults (aged ≥18 years) with T2D and a recent hemoglobin A 1c level of 6.5% or higher was conducted between January 1, 2015, and September 30, 2022, using the TriNetX database. The cohort was divided into 2 groups, adjusted for baseline characteristics through propensity score matching (PSM), based on whether the individuals received prescriptions for a GLP-1 RA. The statistical analysis was conducted on October 10, 2024. Exposures At least 2 prescriptions of a GLP-1 RA given 6 months apart. Main Outcomes and Measures Cox proportional hazard regression models were used to evaluate the primary outcome: association between GLP-1 RAs and the risk of incident DR, NAION, or sight-threatening complications over a 2-year follow-up period. Results After PSM, 185 066 individuals (mean [SD] age, 59.0 [12.5] years; 93 389 females [50.5%]) were prescribed GLP-1 receptor agonists. Use of GLP-1 RAs was associated with an increased incidence of DR (hazard ratio [HR], 1.07; 95% CI, 1.03-1.11), while no statistically significant difference was observed in the risk of NAION (HR, 1.26; 95% CI, 0.94-1.70). In a subgroup analysis of 32 695 patients with preexisting DR, GLP-1 RAs were not associated with progression to proliferative DR (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) but were associated with a lower occurrence of vitreous hemorrhages (HR, 0.74; 95% CI, 0.68-0.80), neovascular glaucoma (HR, 0.78; 95% CI, 0.68-0.88), or blindness (HR, 0.77; 95% CI, 0.73-0.82). Conclusions and Relevance In this cohort study of individuals with T2D, GLP-1 RA use was associated with a modestly increased risk of incident DR; however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.
Outcome Evaluation of Volume-Staged Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations
Mantziaris, Georgios , Hajikarimloo, Bardia , Tos, Salem M , Pikis, Stylianos , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga S., Reda, Wael A. , Tawadros, Sameh R. , Emad, Reem M. , Lunsford, L. Dade , Niranjan, Ajay , Lee, Cheng‐Chia , Sheehan, Darrah, Sheehan, Kimball , Chytka, Tomáš , Meng, Ying , Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju , Jareczek, Frank, Sciscent, Bao Y. , Carrier, Louis, Abdelsalam, Ahmed Ragab , Starke, Robert M. , Benjamin, Carolina , Singh, S.P., Lazo, Erwin , Esquenazi, Yoshua , Blanco, Angel I., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg , Peterson, Jennifer , Chiang, Veronica , Ishaque, Mariam , Sheehan, Jason P. , Bin-Alamer, Othman , Mantziaris, Georgios , Nabeel, Ahmed M. , Reda, Wael A. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Yang, Huai‐Che , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas , Jareczek, Frank, Mathieu, David , Carrier, Louis, Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Chen, Ching‐Jen , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Warnick, Ronald E. , Protopapa, Maria

Mayo Clinic

Neurosurgery | August 11, 2025 | Volume: 98 | Issue: 1 | Pages: 174-184

10.1227/neu.0000000000003682 | PMID 40788018 Get It

BACKGROUND AND OBJECTIVES: Single-session stereotactic radiosurgery (SRS) has limited role for large arteriovenous malformations (AVM). Volume-staged SRS (VS-SRS) is used to optimize outcomes, but studies reporting results are limited. METHODS: This multicenter retrospective cohort of 378 patients from 21 centers reports results of VS-SRS for the entire AVM nidus. We report favorable outcome, obliteration, hemorrhage, and permanent symptomatic adverse radiation effect rates. RESULTS: The median age was 31 years (IQR: 19-44) at the first volume stage, with patients treated in 2–4 stages. The median total nidus volume was 21 cm 3 (IQR: 13.9-30.1 cm 3 ), and a median prescription dose of 17 Gy (IQR: 16-18 Gy) was used. The median radiographic and clinical follow-up were 48 and 55 months, respectively. Seventy-seven patients (20.4%) had a favorable outcome, with the 3-year and 5-year rates being 3.9% and 18%, respectively. 127 patients (33.6%) achieved obliteration, with the 3-year and 5-year rates being 6.8% and 26%, respectively. Obliteration rates of AVMs <15 cm 3 were 81% and 31%, respectively. The latency period hemorrhage incidence rate was 3.02 cases per 100 patient-years; 52 patients (13.8%) had a bleed. Seventy-two patients (19%) had symptomatic adverse radiation effect; in 38 patients (10.1%), these were permanent. Total nidus volume, prescription dose at first stage, diffuse nidus, and prior hemorrhage were all independent affecting outcome rates. CONCLUSION: VS-SRS can be used to treat large AVMs as a standalone treatment. Obliteration rates and favorable outcomes are lower than that with smaller AVMs, and repeat treatment is often required. Optimizing treatment plans, by increasing prescription doses, reducing treatment volume at each stage, and increasing the number of stages, may lead to better outcomes.
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Mékinian, A. , Georgin‐Lavaille, Sophie, Savic, Sinisa , Koster, Matthew J. , Comont, Thibault , Heilblig, Mael, Aróstegui, Juan I. , Bosco, Annmarie , Cargo, Catherine , Cattaneo, Chiara , Chasset, François , Coelho, Henrique , Ducharme‐Bénard, Stéphanie , Frassi, Micol, Hakobyan, Yervand , Jurcuț, Ciprian , Kirino, Yohei , Kunimoto, Hiroyoshi , Madigan, Lauren M. , Moráis, Sara , Sockel, Katja , Patnaik, Mrinal M. , Regadas, Luísa, Robin, Marie , Rutgers, Abraham , Salvarani, Carlo , Sammel, Anthony M. , Sujobert, Pierre , Tomelleri, Alessandro , Vandergheynst, Frédéric , Vieira, Romana, Viswanatha, David S., Diral, Elisa , Terrier, Benjamin , Fenaux, Pierre, Grayson, Peter C. , Beck, David B. , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological, Mékinian, Arsène , Koster, Matthew J , Bourguiba, Rim , Campochiaro, Corrado , Crisafulli, Francesca , Gurnari, Carmelo , Jamilloux, Yvan , Kirino, Yohei , Marvisi, Chiara , Milchert, Marcin , Rutgers, Abraham , Salvarani, Carlo , Tomelleri, Alessandro , Urbanski, Geoffrey , Terrier, Benjamin , Grayson, Peter C , Beck, David B , Robin, Marie , Savic, Sinisa , Georgin‐Lavialle, Sophie , Ferrada, Marcela A. , Kosmider, Olivier , Calvo, Katherine R. , Campochiaro, Corrado , Faria, Raquel , Franceschini, Franco , Groarke, Emma M , Gurnari, Carmelo , Kulasekararaj, Austin , Mann, H. , Marvisi, Chiara , Milchert, Marcin , Muratore, Francesco , Nakajima, Hideaki , Seebach, Jörg Dieter , Więsik–Szewczyk, Ewa , Patel, Bhavisha A. , Fenaux, Pierre , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological

Mayo Clinic

Arthritis & Rheumatology | August 11, 2025 | Volume: 78 | Issue: 3 | Pages: 509-522

10.1002/art.43287 | PMID 40787890 Get It

Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
Maternal Use of Antidepressants in Pregnancy and the Risk of Postpartum Hemorrhage: An Electronic Health Record‐Based Cohort Study
Bobo, William V. , White, Launia J. , Hodge, David O. , Moore, Katherine M. , Betcher, Hannah K. , Larish, Alyssa M., Stoppel, Cynthia , Talati, Ardesheer , White, Launia, Hodge, David, Moore, Katherine, Betcher, Hannah, V Bobo, William

Mayo Clinic

Human Psychopharmacology: Clinical and Experimental | August 9, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1002/hup.70015 | PMID 40782326 Get It

ABSTRACTObjectivesPrior studies have raised concerns about postpartum hemorrhage (PPH) risk associated with selective serotonin and serotonin‐norepinephrine reuptake inhibitors (SSRIs and SNRIs), although limitations include possible confounding by maternal indications. The current study examined the risk of PPH associated with prenatal S/NRIs accounting for diagnosed maternal depression during pregnancy.MethodsThe current study is a secondary analysis of data from a cohort of 2213 pregnancies (1997–2010) identified from a large electronic medical record‐linkage system. Exposures were identified from electronic prescriptions records and resulted in three main groups: S/NRI‐exposed pregnancies (S/NRI users), antidepressant‐unexposed pregnancies (non‐users), and S/NRI exposure in the year prior to (but not during) pregnancy (former users). Data used to identify PPH occurrences included obstetrician chart diagnoses, diagnosis codes, and recorded estimated blood loss (EBL). The risk of PPH by exposure group was estimated using unadjusted, minimally adjusted (maternal age at delivery, delivery year, parity, and maternal smoking), and depression‐adjusted models (previous covariates and maternal depression). Supplemental analyses included an examination of PPH risk with prenatal bupropion monotherapy.ResultsThe study cohort consisted of 837 S/NRI users, 401 former users, and 786 non‐users, as well as 114 bupropion users identified for additional analyses. The frequency of PPH was 11.6% in the overall cohort, and was 14.7% for S/NRI users, 10.2% for former users, and 8.7% for non‐users. The risk of PPH was significantly higher for S/NRI users than non‐users in unadjusted (OR 1.82 [95% CI 1.33, 2.49]), minimally adjusted (aOR 1.66 [1.19, 2.31]), and depression‐adjusted models (aOR 1.46 [1.02, 2.10]). The risk of PPH was also higher for S/NRI former users than non‐users in unadjusted models (OR 1.54 [1.05, 2.26]) but not minimally adjusted (aOR 1.42 [0.95, 2.11]) or depression‐adjusted models (aOR 1.41 [0.95, 2.10]). No significant differences in PPH risk were observed between S/NRI users and former users, between bupropion users and non‐users, or between S/NRI users and bupropion users.ConclusionsPrenatal S/NRI exposure was associated with an increased risk of PPH after adjusting for maternal depression, although residual confounding and confounding by other factors (including unmeasured factors) may be possible, as the risk of PPH appeared to be similar between S/NRI users and former users. Best‐practice PPH risk management strategies should be adhered to for depressed patients, especially those who require treatment with antidepressants during pregnancy.
DNA Immunotherapy ( INO ‐3107) Results in Long‐Term Surgery Reduction in RRP
Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Pransky, Seth M. , Welsh, Christopher, Slog, Stefani A., Gillespie, Elisabeth, Dallas, Michael, Morrow, Matthew P. , Skolnik, Jeffrey , Best, Simon R , Lott, David G , Mau, Ted , Paniello, Randal C , Slog, Stefani A , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Welsh, Christopher, Dallas, Michael J.

Mayo Clinic

The Laryngoscope | August 9, 2025 | Volume: 135 | Issue: 11 | Pages: 4287-4295

10.1002/lary.32416 | PMID 40781903 Get It

ABSTRACT Objective To evaluate the long‐term safety and clinical effect of INO‐3107 immunotherapy in adults with recurrent respiratory papillomatosis (RRP). Methods RRP‐002 was a retrospective, observational extension study that followed patients enrolled in the 52‐week RRP‐001 study. Patients with moderate to severe juvenile or adult‐onset RRP who had undergone ≥ 2 surgical interventions in the year preceding dosing were eligible for enrollment in RRP‐001. Participants underwent surgical debulking within 14 days prior to initial dosing and then received INO‐3107 on Day 0, Weeks 3, 6, and 9. Efficacy assessments during RRP‐002 follow‐up were the frequency of surgical interventions and alternative medication use. The safety evaluation included reported serious adverse events (SAEs). Results Twenty‐eight (28) of 32 participants from the 52‐week RRP‐001 study were enrolled in RRP‐002. The median follow‐up time for RRP‐002 was 1.8 years (range: 1.2–2.4 years) for a total median assessment time of 2.8 years (range: 1.0–3.5 years). There were no SAEs or long‐term safety concerns identified. The mean number of surgeries was reduced from 4.1 in the pre‐treatment period to 1.7 in the first year post‐INO‐3107 treatment (Year 1) to 0.9 in the second year (Year 2). The complete response rate (0 surgeries per year) increased from 28% (9/32) in Year 1 to 50% (14/28) in Year 2. Conclusion INO‐3107 is well tolerated and provides a continued clinical effect against HPV‐6 and 11 RRP that results in further reduction of the surgical burden observed in Year 1. These data support the role of INO‐3107 immunotherapy for adult patients with RRP. Level of Evidence: III.
Efficacy of cenobamate in tumor‐related epilepsy
Chiriboga, Guido , Safa, Adrian , Tatum, William O. , Freund, Brin , Feyissa, Anteneh, Burkholder, David B , Mirsattari, Seyed, Freund, Brin E , Feyissa, Anteneh M. , Noe, Katherine H. , Burkholder, David B. , Mirsattari, Seyed M. , ReFaey, Karim

Mayo Clinic

Epileptic Disorders | August 8, 2025 | Volume: 27 | Issue: 6 | Pages: 1178-1186

10.1002/epd2.70081 | PMID 40778748 Get It

Abstract Purpose Cenobamate is approved for treating focal epilepsy and has potential for treating tumor‐related epilepsy (TRE) based on potential anti‐tumor effects, though there is little data on efficacy and safety in this patient population. Methods This was a retrospective, multi‐center study of patients with TRE who were prescribed cenobamate as adjunctive treatment between January 2020 and November 2024 at Mayo Clinic in Florida, Minnesota, and Arizona. Drug efficacy was assessed, and factors that were predictive of response to treatment were analyzed. Results A total of 17 patients were included, with 12 being drug resistant. The median seizure frequency for the entire group before starting cenobamate treatment was 12 (IQR = 4–64) per month, and after treatment at last follow‐up was 3 (IQR = 1–15) per month, with an overall 56.3% reduction. Four patients (23.5%) were seizure‐free, and 7 (41.1%) patients were responders (at least 50% seizure reduction). No adverse events were reported for patients on concurrent chemotherapy. Responders had significantly fewer seizures per month compared to non‐responders (5.72 ± 10.29 vs. 27.33 ± 30.17; p = .030). No clinical factors were predictive of responsiveness (or lack thereof) to cenobamate. Conclusions This study demonstrates that adjunctive therapy with cenobamate treatment for TRE is a feasible and potentially effective option. Clinical history, including drug resistance, did not predict drug efficacy. No adverse effects were reported in those treated with chemotherapy. Further studies are needed to validate treatment response and safety.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.